

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) **April 25, 2018**

**LEXARIA BIOSCIENCE CORP.**

(Exact name of registrant as specified in its charter)

**Nevada**  
(State or other jurisdiction of  
incorporation)

**000-52138**  
(Commission File Number)

**20-2000871**  
(IRS Employer  
Identification No.)

**156 Valleyview Road, Kelowna, BC Canada**  
(Address of principal executive offices)

**V1X 3M4**  
(Zip Code)

Registrant's telephone number, including area code **(250) 765-6424**

**N/A**  
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)  
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 1.01 Entry into a Material Definitive Agreement**

On April 25, 2018, Lexaria announced it has entered a definitive technology licensing agreement (the "Agreement") with GP Holdings LLC. ("GP") whereby Lexaria is providing its patented DehydraTECH™ technology to empower next-generation performance in high absorption, fast acting cannabis infused beverages to be developed and sold in California.

---

GP has acquired 5-year semi-exclusive rights to use Lexaria's DehydraTECH™ technology for beverage applications within California for an undisclosed sum and a royalty on revenue generated on products sold utilizing DehydraTECH™. In addition, GP also intends to develop topical skin products using the technology and has also acquired matching rights for this application.

**Item 7.01 Regulation FD Disclosure**

A copy of the news release announcing that Lexaria has commenced a clinical study in Europe to evaluate the cardiovascular and cognitive health effects of Lexaria's high absorption TurboCBD™ capsules is filed as exhibit 99.1 to this current report and is hereby incorporated by reference.

A copy of the news release announcing that Lexaria has entered a definitive technology licensing agreement (the "Agreement") with GP Holdings LLC is filed as exhibit 99.2 to this current report and is hereby incorporated by reference.

**Item 9.01 Financial Statements and Exhibits**

[10.1 Technology License Agreement dated April 20, 2018](#)

[99.1 Press Release dated April 23, 2018](#)

[99.2 Press Release dated April 25, 2018](#)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**LEXARIA BIOSCIENCE CORP.**

*/s/ Chris Bunka*

**Chris Bunka**

CEO, Principal Executive Officer

Date: April 25, 2018

---

**INTELLECTUAL PROPERTY LICENSE**  
**#2018US04**

This document certifies that an Intellectual Property License dated as of April 20, 2018 has been granted by:

**Lexaria Bioscience Corp.**, a Nevada corporation with offices at 156 Valleyview Rd, Kelowna, British Columbia, V1X 3M4, Canada (“**Licensor**”, “**Lexaria**”, “**us**”, “**our**”, “**we**”),

To:

**GP Holdings, LLC** a California limited liability company c/o Heath Steinbeck, LLP, 5777 W Century Blvd., Ste. 765, Los Angeles, CA 90045 (together with its successors and assigns “**GP**”, “**Licensee**”, “**you**”, “**your**”).

**RECITALS**

WHEREAS certain capitalized terms not otherwise defined below are defined in **Exhibit “D”** herein;

WHEREAS, LICENSEE is directly (or indirectly through a partner, as further contemplated in Section 1(a) below) engaged in the business of developing, manufacturing, and selling cannabis-infused products pursuant to licenses issued by the authorities relevant in each and every geographic location referenced within this Agreement, pursuant to regulations promulgated thereby;

WHEREAS, LICENSOR owns and holds, and will make improvements from time to time, on certain intellectual property and technology (“**Technology**”) related to, including but not limited to, the development, testing, and manufacturing process for marijuana-infused products, which Technology is more specifically described in **Exhibit “A”**;

WHEREAS, LICENSEE wishes to utilize the Technology (which shall include any Licensor’s Improvements) of LICENSOR, and LICENSOR desires for LICENSEE to utilize the Technology, to create, test, manufacture and sell, either on its own account or as a contract manufacturer, Consumable Liquids and/or Topical Skin Products (“**End Products**,” as further described in Exhibit B), subject to the terms and conditions set forth herein;

WHEREAS, such End Products shall only be distributed and/or sold by LICENSEE or its Partner as defined in Section 1.a below in compliance with all local and state, licensing requirements applicable to the cannabis industry within the State of California in the case of marijuana-infused End Products and nationwide in the U.S. in the case of hemp-infused End Product devoid of marijuana-derived inputs, or in any other location in which LICENSEE is permitted by this Agreement or an addendum to this Agreement to sell or distribute the End Products (such locations collectively referred to as “**Territory**”);

WHEREAS, the End Products may not be exported from the Territory to any other global location without express written permission granted in advance from the LICENSOR and is subject to entering a separate licensing agreement or by addendum to this Agreement, and always subject to availability among other LICENSOR considerations; and

WHEREAS, the Parties intend and desire for these recitals to be incorporated into the Agreement, and to be bound by any representations or obligations contained therein.

---

NOW, THEREFORE, in consideration of the promises and the respective covenants and agreements of the parties contained in this Agreement, the Parties hereto agree as follows:

## LICENSE

1. **License of Technology:** Subject to certain terms and conditions, LICENSOR hereby grants to LICENSEE each of the licenses more fully defined in Section 2 below.
  - a) **Non-transferable:** The license granted by this Section 1 may not be transferred or sublicensed by LICENSEE without LICENSOR's written consent. However, LICENSEE has the right to sublicense its license to any entity within the GP Group.
  - b) **Other Products:** The Parties agree that LICENSEE is not limited to production of the End Products defined herein, but that LICENSEE may develop, create and test new products that are derived from or otherwise incorporate the Technology and such new products are only to be distributed and/or sold to Permitted Locations (the "New Products"), subject to availability of licenses in the future from Lexaria.
- 2) **Semi-exclusivity and Non-exclusive Licenses and License Option.** LICENSEE will have the following rights to produce and sell the End Products during the Term (as defined in Section 4, below) in the Territory using the Technology licensed pursuant to this Agreement.

- a) **In the Territory:**

- i) Semi-exclusive rights from the effective date until five (5) years after the Effective date, allowing LICENSEE the semi-exclusive ability to continue to manufacture the marijuana infused End Products directly or through its Partner in the Territory for the balance of the term of this Agreement as per Section 4. Semi-exclusive under this Agreement means that LICENSOR will not permit more than four (4) such licenses at any time for the marijuana-infused End Products utilizing its Technology to be granted within each single Territory, including the license granted to LICENSEE, and its named Partner if so named as provided in Section 1(a), under this Agreement.

- b) **In the Territory:**

Non-exclusive rights from the effective date until five (5) years after the Effective date, allowing LICENSEE the non-exclusive ability to continue to manufacture the hemp-infused End Products directly or through its Partner in the Territory for the balance of the term of this Agreement as per Section 4.

- c) **License Option:**

- i) Furthermore, until September 23, 2019, LICENSOR will with limitations reserve one license in each of the States of Colorado, Illinois, and New Jersey and the country of Canada (including all territories and provinces) for the benefit of LICENSEE to be semi-exclusive in the case of the End Products, to distribute and/or sell End Products in locations compliant with all local and state laws applicable therein; under this option arrangement (the "**License Option**"). LICENSEE shall be provided 30 calendar days notice in writing until September 23, 2019 if the final semi-exclusive license or any exclusive license available in any member state, under this License Option is under serious negotiation with another party. The LICENSEE will have the option of receiving the final semi-exclusive license therein, or an exclusive license as applicable, simply by agreeing to improve upon the financial terms offered by the party with which the Licensor is negotiating. If and only at such time as LICENSEE notifies LICENSOR that it wants to sell or cause to sell directly or through a Partner, as described in Section 1(a), any End Products utilizing the Technology in any or all of these additional states ("**Exercise of License Option**"), then LICENSEE does hereby agree to a license of the Technology for each state into which it has exercised the License Option that is substantially similar to this Agreement, including that LICENSEE agrees to pay appropriate Territory License fees and Usage fees in each state optioned in accordance with the OPTION ("**Subsequent License Agreement**"). Each Subsequent License Agreement shall have a term of not less than three (3) years from the date of signing the Subsequent Agreement. All such Subsequent License Agreements shall follow to the greatest extent possible the same terms of this Agreement. Subsequent License Agreements shall be considered "entered into by the Parties" and effective by both Parties executing a written addendum to this Agreement acknowledging that the Parties have entered into any such Subsequent License Agreement.
-

- d) **LICENSOR's Products:** LICENSOR shall not be prohibited from (i) licensing or similar arrangements with respect to the Technology outside of the Territory, subject to the License Option set forth above; or (ii) licensing its Technology on the semi-exclusive basis provided for herein, at all times and in all locations, subject to the terms of this Agreement, including the exclusivity and semi-exclusivity provisions and License Options. Subject to its rights and obligations under this Agreement, LICENSOR is otherwise expressly permitted to utilize its Technology on any basis it chooses, at any time, for producing and commercializing its own products, provided, however, that LICENSOR would be considered as one of the four (4) permitted licensees in any Territory where LICENSEE retains semi-exclusive rights.
- 3) **Rights and Obligations Related to the Technology.** Except as expressly provided in this section or elsewhere in this Agreement, neither Party will be deemed by this Agreement to have been granted any license or other rights to the other Party's products, information or other intellectual property rights, either expressly or by implication, estoppel or otherwise.
- a) **LICENSOR Intellectual Property:** LICENSOR retains full, absolute, and complete rights to all processes covered or described in all of its issued patents and its patent applications filed prior to the date of this Agreement, and any future continuations, continuations in part or divisional applications filed thereto, including but not limited to the US Provisional patent applications, US Utility patent application, and the International patent application, that comprise the Technology ("**Licensor IP**"), unless LICENSOR allows these applications to abandon or lapse, or otherwise fails to protect the Technology. Except as expressly provided for in Section 2, nothing in this Agreement or in the conduct of the Parties shall be interpreted as preventing LICENSOR from granting to any other person a license for use of the Technology or from using the Technology in any manner whatsoever.
- b) **LICENSEE Intellectual Property:** Any intellectual property resulting solely from LICENSEE's work, know-how, or development that does *not* include nor rely upon the Technology, Licensor IP or jointly owned intellectual property, as described in this Agreement, shall be owned by LICENSEE ("**Licensee IP**").
- c) **Improvements:**
- i) **LICENSOR Improvements:** The entire right and title to the Technology, whether or not patentable, and any patent applications or patents based thereon, which directly relate to and are not severable from LICENSOR IP and which are improvements thereto by LICENSOR, its employees or others acting solely on LICENSOR's behalf shall be owned solely by LICENSOR ("**Licensor Improvements**").
-

- ii) LICENSEE Improvements: Rights and title to improvements whether or not patentable, and any patent applications or patents based thereon, which directly relate to and are not severable from LICENSOR IP and which are improvements thereto by LICENSEE, its employees or its Partner, as defined by this Agreement, shall be owned by the LICENSEE ("Licensee Improvements"). In respect to such Licensee Improvements, LICENSOR grants LICENSEE a license to use the underlying intellectual property supporting any such improvement for so long as this Agreement remains in effect (including any renewal terms) and LICENSOR agrees to negotiate in good faith terms of license renewal after the end of the Term of this Agreement and any renewal terms per Section 4a. If LICENSEE develops any Licensee Improvements, LICENSEE will promptly provide LICENSOR with written notice of such Licensee Improvements to validate LICENSEE'S claim to Licensee Improvements. Following receipt of notice of such Licensee Improvements, LICENSOR shall have the exclusive option during the Term of this Agreement (and any renewal terms) to purchase or license from LICENSEE the Licensee Improvements for LICENSOR's use upon mutually agreeable terms and conditions that the parties shall negotiate in good faith.
  - iii) Joint Improvements: Rights and title to the Technology, whether or not patentable, and any patent applications or patents based thereon, which directly relate to and are not severable from LICENSOR IP and which are improvements thereto by both LICENSOR AND LICENSEE shall be jointly owned intellectual property by LICENSOR AND LICENSEE.
  - iv) Improvements: Assignment. LICENSEE and LICENSOR hereby represent that all Partners, employees and other persons acting on its behalf in performing its obligations under this Agreement shall be obligated under a binding written agreement to assign, or as it shall direct, all Joint Improvements that include or rely on the Technology conceived or reduced to practice by such Partners, employees or other persons acting on its behalf in accordance with this Agreement to the benefit of LICENSOR and LICENSEE.
  - v) Improvements: Confidential Information. All Improvements shall constitute Confidential Information and shall be subject to the confidentiality provisions set forth in this Agreement.
- d) **Inventions: Reporting**:
- i) Upon making any invention that does *not* include or rely upon the Technology LICENSEE has no obligation to share such information of invention with LICENSOR nor inform LICENSOR of said invention, and LICENSEE retains unrestricted rights and ability to use, assign, license, seek patent and other forms of intellectual property protection related to said invention. For the avoidance of doubt, any such new invention, development, technology, and/or intellectual property belongs solely to LICENSEE. Upon making any invention that does or does not include or rely upon the Technology, LICENSOR has no obligation to share such information of invention with LICENSEE nor inform LICENSEE of said invention, and LICENSOR retains unrestricted rights and ability to use, assign, license, seek patent and other forms of intellectual property protection related to said invention.
- e) **Jointly Owned Intellectual Property**: If any patent applications are filed seeking to protect any Joint Improvements ("**Jointly Owned IP**"), each Party shall be named as joint inventors.
- i) Prosecution and Maintenance of Jointly Owned Patents. The Parties shall cooperate to cause the filing of one or more patent applications covering any such Jointly Owned IP. The Parties will mutually agree upon which of them shall be responsible for filing, prosecution and maintenance of Jointly Owned IP. The expenses of such filing, prosecution and maintenance shall be equally shared by the Parties unless one of the Parties assigns all of its rights to the other Party. Both Parties agree to assist the other Party in enforcing its rights in the Jointly Owned IP. The costs of any such assistance or cooperation will be borne by the requesting party.
-

- ii) **Jointly Owned IP Rights.** LICENSOR grants to LICENSEE an exclusive, non-sub-licensable, fully-paid, royalty-free, perpetual license to any Jointly Owned IP. Further, LICENSEE grants to LICENSOR an exclusive, non-sub-licensable, fully-paid, royalty-free, perpetual license to any Jointly Owned IP.
  - f) **No Challenge.** LICENSEE expressly acknowledges and agrees that all rights in and to the Technology shall remain vested in LICENSOR, and LICENSEE shall not assert any rights to the Technology except as otherwise provided in this Section 3.
  - g) **Notice Requirements.** To the extent required by applicable rules and regulations, including those of DPBH related to packaging, LICENSEE agrees that it will include such patent notices and other proprietary notices on all End Products or related materials that contain any Technology as may be reasonably required by DPBH or other regulators in order to give appropriate notice of all intellectual property rights therein or pertaining thereto.
  - h) **Quality Control.**
    - i) LICENSEE agrees to maintain and preserve the quality of the Technology, and to use the Technology in good faith and in a manner consistent with the uses approved herein.
    - ii) LICENSEE shall ensure that all End Products and related materials under the Technology are developed, tested, promoted, manufactured and distributed in a professional manner in compliance with any and all applicable laws, rules and regulations.
- 4) **Term and Termination; Option to Renew.**
- a) **Term.** This Agreement shall take effect upon signing by both Parties and shall remain in effect for the shorter of either five (5) years; or, such circumstances as described in Section 4.d (the “Term”).
  - b) **Termination.** This Agreement and the licenses granted hereunder may be terminated prior to the expiration of the Term or any renewal term of this Agreement as follows:
    - i) This Agreement may be terminated by LICENSOR by written notice to LICENSEE upon the occurrence of any of the following: (i) failure of LICENSEE to pay any license fees for more than sixty (60) days after they become due; (ii) LICENSEE’s violation of the provisions of Sections 7 and 8 or LICENSEE’s material breach of any other term of this Agreement, which violation and/or breach is not cured within sixty (60) days after written notice of such breach from LICENSOR; (iii) failure of LICENSEE to maintain all required licenses and governmental authorizations required for the conduct of its business or to comply in all material respects with applicable laws; or (iv) LICENSEE ceases operations, makes a general assignment for the benefit of creditors, or is the subject of a voluntary or involuntary bankruptcy, insolvency or similar proceeding.
    - ii) This Agreement may be terminated by LICENSEE by written notice to LICENSOR in the event of material breach by LICENSOR of its obligations or representations and warranties under this Agreement, which breach is not cured within sixty (60) days after written notice of such breach from LICENSEE.
  - c) **Effect of Termination.** Except as provided for in Section 4, LICENSEE’s payment obligations shall extinguish if this Agreement is terminated. If the Agreement expires without any renewal thereof, then LICENSEE must immediately cease and desist all utilization of the Technology to manufacture, distribute or sell End Products, except that it may distribute and sell End Products until all finished goods and raw materials inventory that pertains to the Technology has been sold. In any event, upon the natural future expiration of all pending and issued patents as applicable related to the Technology described herein the License Agreement shall expire and LICENSEE shall have no further payment obligations to LICENSOR.
-

d) Option to Extend (California). Pursuant to this Section 4.d, LICENSOR grants LICENSEE an option to extend the Term, for the State of California only, for an additional five (5) years from the end of the Term (the “**Option to Extend**”). In the event LICENSEE elects to exercise the Option to Extend, this Agreement shall continue under the same terms, conditions, and obligations contained herein and agreed upon by the Parties upon the execution hereof. As good and sufficient consideration for grant of this Option to Extend, LICENSEE shall pay LICENSOR one thousand dollars (\$1,000) upon execution of this Agreement, which shall be non-refundable and not credited against any other payments due to LICENSOR under this Agreement. Should LICENSEE elect to exercise the Option to Extend, it will be required to meet certain financial obligations at that time.

5) **Indemnification.**

- a) LICENSEE agrees to indemnify LICENSOR and hold LICENSOR harmless from and against any and all liabilities, losses and expenses arising from (i) LICENSEE’s unauthorized use of the Technology; (ii) LICENSEE’s failure to comply with applicable laws or to maintain all required licenses and governmental authorizations; (iii) any breach of LICENSEE’s representations and warranties set forth herein; and (iv) any liability to third parties as a result of LICENSEE’s production, distribution and/or sale of End Products, except as to any liability arising out of the proper use of the Technology.
- b) LICENSOR agrees to indemnify LICENSEE and hold LICENSEE harmless from and against any and all liabilities, losses and expenses arising from (i) any breach of LICENSOR’s representations and warranties set forth herein; and (ii) any claims of infringement raised by third parties as to the Technology or Licensed Patents, as provided more fully in Section 2(k) of this Agreement.

6) **Confidentiality.** In addition to the Confidentiality Agreement previously entered into by the Parties, at all times during the term of this Agreement (including any renewal term) and thereafter, LICENSEE will not use or disclose and will otherwise keep confidential any trade secrets or proprietary information, including, but not limited to the Technology and other intellectual property of LICENSOR (collectively, the “**Confidential Information**”) except to the extent required to perform its obligations under this Agreement. Without limitation of the foregoing, LICENSEE will hold the Confidential Information in confidence and will (a) exercise the same degree of care, but no less than a reasonable degree of care, to prevent its disclosure as LICENSEE would take to safeguard its own confidential or proprietary information, and (b) limit disclosure of Confidential Information, including any notes, extracts, analyses or materials that would disclose Confidential Information, solely to those of its employees who need to know the information for purposes of performing its obligations under this Agreement and who agree to keep such information confidential. Upon termination of this Agreement, LICENSEE shall immediately return all Confidential Information to LICENSOR and LICENSOR shall have the right to conduct an on- site audit of the LICENSEE within three (3) business days of termination to ensure compliance with the terms of this Agreement, at LICENSOR’S expense.

- a) Limitations. This section does not apply to any information that: (a) is already lawfully in the receiving Party’s possession (unless received pursuant to a nondisclosure agreement); (b) is or becomes generally available to the public through no fault of the receiving Party; (c) is disclosed to the receiving Party by a third party who may transfer or disclose such information without restriction; (d) is required to be disclosed by the receiving Party as a matter of law (provided that the receiving Party will use all reasonable efforts to provide the disclosing Party with prior notice of such disclosure and to obtain a protective order therefor, with all costs to be borne by the disclosing Party); (e) is disclosed by the receiving Party with the disclosing Party’s approval; or (f) is independently developed by the receiving Party without any use of confidential information. In all cases, the receiving Party will use all reasonable efforts to give the disclosing Party ten (10) days’ prior written notice of any disclosure of information under this Agreement. The Parties will maintain the confidentiality of all confidential and proprietary information learned pursuant to this Agreement for a period of ten (10) years from the date of termination of this Agreement.
-



b) Saving Provision. The Parties agree and stipulate that the agreements contained in this Section are fair and reasonable in light of all of the facts and circumstances of their relationship; however, the Parties are aware that in certain circumstances courts have refused to enforce certain agreements. Therefore, in furtherance of and not in derogation of the provisions of the preceding paragraph the parties agree that in the event a court should decline to enforce the provisions of the preceding paragraph, that paragraph shall be deemed to be modified to restrict non-enforcing Party's rights under this Agreement to the maximum extent, in both time and geography, which the court shall find enforceable.

7) **Limitation of Liability.** EXCEPT TO THE EXTENT OTHERWISE EXPRESSLY AGREED TO IN THIS AGREEMENT, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR LOST PROFITS OR FOR ANY DIRECT, INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES IN CONNECTION WITH THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT, HOWEVER CAUSED, UNDER ANY THEORY OF LIABILITY. THE FOREGOING SHALL NOT LIMIT LICENSEE'S LIABILITY FOR UNAUTHORIZED USE BY LICENSEE OF LICENSOR'S TECHNOLOGY.

8) **No Warranties. OTHER THAN THE EXPRESS WARRANTIES PROVIDED HEREIN,**

LICENSOR MAKES NO EXPRESS WARRANTIES OF MERCHANTABILITY OR FITNESS OR EFFICACY FOR A PARTICULAR PURPOSE OF THE TECHNOLOGY AND/OR ANY END PRODUCTS PRODUCED FROM SAID TECHNOLOGY AND SHALL NOT BE HELD LIABLE FOR PROFITABILITY OF TECHNOLOGY AND/OR END PRODUCTS OR HELD LIABLE UNDER ANY OTHER THEORY OF LIABILITY.

NOW, THEREFORE, in consideration of the premises and the mutual promises and conditions hereinafter set forth, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, do hereby agree.

**IN WITNESS WHEREOF,** Lexaria Bioscience Corp has granted this license.

**"LICENSOR"  
LEXARIA BIOSCIENCE CORP.**

/s/ Chris Bunka, CEO

---

**EXHIBIT A**

**TECHNOLOGY**

The Technology consists of:

(1) the following patent applications, patents granted, and PCT International Patent Applications; (2) all technical know-how and trade secrets in regard to such named patents, including the use, manufacture or formulation thereof, that is owned or controlled by LICENSOR as of the Effective Date of this Agreement, as well as any future continuations, continuations in part or divisional applications filed pursuant to the patent applications. (the "**Licensed Patents**");

U.S. Patent Granted No. 9,474,725 awarded October 27, 2016.

U.S. Patent Granted No. 9,839,612 B2 awarded December 12, 2017

U.S. Provisional Patent Application No. 62/010,601.

U.S. Provisional Patent Application No. 62/037,706.

U.S. Provisional Patent Application No. 62/153,835.

U.S. Provisional Patent Application No. 62/161,324.

U.S. Notice of Allowance (March 2018) for Provisional Patent Application No. 15/225,802.

U.S. Provisional Patent Application No. 15/225,802.

U.S. Provisional Patent Application No. 62/264,959.

U.S. Provisional Patent Application No. 62/264,967.

U.S. Utility Patent Application No. 14/735,844.

PCT International Patent Application No. PCT/US15/35128.

PCT International Patent Application No. PCT/US16/64295.

PCT International Patent Application No. PCT/US16/64296.

National filings thereunder:

2949369,

201580031524.X,

15806768.6,

201647041745.00

516371405

Australian Patent Granted No. 2015274698 awarded June 15, 2017

---

**EXHIBIT B**

**END PRODUCTS**

<b>Product Line Name</b>	<b>Product Line Description</b>
Consumable Liquids	Any consumable liquid products including, but not limited to, cold brew or hot coffee, teas, lemonades, flavored waters, juices, protein drinks, sport drinks, cocoa drinks, kombuchas, probiotics, energy drinks/shots, vitamin waters, tinctures, essential oils, olive oils, flavored concentrates, dressings, honeys and syrups, flavored sprays or sauces for consumption by way of ingestion that are infused with hemp and/or marijuana oil.
Topical Skin Products	Any cream, oil, salve or similar consumer product designed to be delivered to and through human skin that is infused with hemp and/or marijuana oil.

---

### Lexaria Announces Human Clinical Study on CBD Absorption Underway

Kelowna, British Columbia – April 23, 2018 – Lexaria Bioscience Corp. (OTCQX: LXR) (CSE: LXX) (the “Company” or “Lexaria”), a drug delivery platform innovator, is pleased to announce that it has commenced a clinical study in Europe to evaluate the cardiovascular and cognitive health effects of Lexaria’s high absorption TurboCBD™ capsules.

The pharmacokinetic and pharmacodynamic data generated by this study will provide objective human performance findings that will assist in the development of the Company’s next-generation cannabinoid product formulations and be of significant benefit to the Company and its partners.

The study employs a double-blind and placebo-controlled cross-over design measuring TurboCBD™ effects both after a single 45mg dose and, on a separate day, after a single 90mg dose in 12 healthy male volunteers. The study hypothesises that, following TurboCBD™ supplementation, circulating CBD and nitric oxide will increase in most participants; that glucose and blood pressure will remain stable; and that vascular function, and cognitive performance will improve. The same DehydraTECH™ technology is being used to deliver CBD in this human study, as was used by the Company in its recent rodent-based nicotine absorption study, illustrating the wide applicability of the Company’s patented drug delivery platform.

This advanced study will utilize the latest clinical evaluation techniques to provide pharma-level pharmacokinetic and pharmacodynamic performance data of TurboCBD™, including blood sampling, physiological measures, cognitive function testing and cardiovascular function testing. Outcome measurements will include circulating CBD and nitric oxide markers, plasma glucose, plasma insulin, blood pressure, heart rate, respiration, peripheral and brain blood flow and a battery of neuropsychological performance tests.

This study was originally intended to be conducted at the University of British Columbia but policy change has resulted in a move to a medical university in Europe, where it is presently being conducted. Study results are expected within 90 days. Depending on results, a second phase clinical study in elderly is already designed and has received necessary regulatory approvals and could commence later in 2018.

Breakthrough Nicotine Absorption Results To Be Presented Tomorrow in Atlanta, GA. Separately, Lexaria announces that it is presenting the results of its recent breakthrough nicotine absorption study at the *Next Generation Nicotine Delivery 2018 USA* conference April 24th & 25th 2018, in Atlanta, USA. The Company has two prominent speaking appointments to present their latest ingestible nicotine absorption breakthrough: [Link](#)

---

To an audience of big tobacco players and regulatory representatives, Lexaria is presenting the only truly novel and unique approach to new nicotine product delivery in the industry today.

#### About Lexaria

Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECH™ delivery technology. Lexaria's technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. [www.lexariabioscience.com](http://www.lexariabioscience.com)



For regular updates, connect with Lexaria on Twitter (<https://twitter.com/lexariacorp>) and on Facebook <http://tinyurl.com/y8vzcaam>

#### FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Bioscience Corp.  
Alex Blanchard, Communications Manager  
(778) 796-1897  
Or  
NetworkNewsWire (NNW)  
[www.NetworkNewsWire.com](http://www.NetworkNewsWire.com)

#### FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements, including but not limited to: that any additional patent protection will be realized or that patent achievements will deliver material results. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that existing capital is sufficient for the Company's needs or that it will be able to raise additional capital. There is no assurance the Company will be capable of developing, marketing, licensing, or selling edible products containing cannabinoids, nicotine or any other active ingredient. There is no assurance that any planned corporate activity, scientific research or study, business venture, technology licensing pursuit, patent application or allowance, consumer study, or any initiative will be pursued, or if pursued, will be successful. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease.

*The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.*

---

**Lexaria Enters Definitive License Agreement with California Cannabis Beverage Manufacturer**

Kelowna, British Columbia – April 25, 2018 – Lexaria Bioscience Corp. (OTCQX: LXP) (CSE: LXX) (the “Company” or “Lexaria”) a drug delivery platform innovator, announces it has entered a definitive technology licensing agreement (the “Agreement”) with GP Holdings LLC. (“GP”) whereby Lexaria is providing its patented DehydraTECH™ technology to empower next-generation performance in high absorption, fast acting cannabis infused beverages to be developed and sold in California.

GP is establishing its operation as the leading THC beverage contract manufacturer in the state of California and expects the commencement of operations from its new state-of-the-art bottling facility within the next two quarters. Lexaria and GP have been collaborating for months to develop the highest performing cannabis beverages available anywhere, with nearly zero unwanted cannabis odor or flavor, and complete clarity and transparency of even sparkling beverages. More info about GP can be found at [www.growpacker.com](http://www.growpacker.com)

GP has acquired 5-year semi-exclusive rights to use Lexaria’s DehydraTECH™ technology for beverage applications within California for an undisclosed sum and a royalty on revenue generated on products sold utilizing DehydraTECH™. In addition, GP also intends to develop topical skin products using the technology and has also acquired matching rights for this application.

The California cannabis-beverage market is expected to be one of the largest edible product segments, and this agreement continues Lexaria’s progress of building an international ecosystem empowering licensed producers of all sizes with the ability to create best-of-class sector leaders. Under the terms of the semi-exclusive Agreement, Lexaria can offer other licensee partners the option of utilizing GP’s formulation and manufacturing expertise to produce cannabis infused, DehydraTECH™-powered beverages and topicals throughout the state of California.

“The use of DehydraTECH™ triggers a race to the top in the California THC beverage and topicals market through this 5-year license agreement,” said Chief Executive Officer Chris Bunka. “This is another long-term strategic relationship that will give consumers the faster acting and highly potent products they deserve, and class leading flavor profiles for the beverage segment in particular.”

---

## About Lexaria

Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECH™ delivery technology. Lexaria's technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. [www.lexariabioscience.com](http://www.lexariabioscience.com)



For regular updates, connect with Lexaria on Twitter (<https://twitter.com/lexariacorp>) and on Facebook <http://tinyurl.com/y8vzcaam>

### FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Bioscience Corp.  
Alex Blanchard, Communications Manager  
(778) 796-1897

Or  
NetworkNewsWire (NNW)  
[www.NetworkNewsWire.com](http://www.NetworkNewsWire.com)

### FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements, including but not limited to: that any additional patent protection will be realized or that patent achievements will deliver material results. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that existing capital is sufficient for the Company's needs or that it will be able to raise additional capital. There is no assurance the Company will be capable of developing, marketing, licensing, or selling edible products containing cannabinoids or any other active ingredient, or that the GP Holdings license agreement will successfully produce benefits to the Company. There is no assurance that any planned corporate activity, scientific research or study, business venture, technology licensing pursuit, patent application or allowance, consumer study, or any initiative will be pursued, or if pursued, will be successful. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease.

*The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.*

---